Evidence map›Paper›PMID 30801908›Full record

ArticleCancer science2019

Therapeutic efficacy evaluation of radioimmunotherapy with

Hitomi Sudo, Atsushi B Tsuji, Aya Sugyo, Tsuneo Saga, Mika K Kaneko, Yukinari Kato, Tatsuya Higashi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Hitomi SudoDepartment of Molecular Imaging and Theranostics, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology (QST-NIRS), Chiba, Japan.
Atsushi B TsujiDepartment of Molecular Imaging and Theranostics, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology (QST-NIRS), Chiba, Japan.ORCID https://orcid.org/0000-0003-2726-288X
Aya SugyoDepartment of Molecular Imaging and Theranostics, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology (QST-NIRS), Chiba, Japan.
Tsuneo SagaDepartment of Diagnostic Radiology, Kyoto University Hospital, Kyoto, Japan.ORCID https://orcid.org/0000-0001-7801-9316
Mika K KanekoDepartment of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Yukinari KatoDepartment of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.ORCID https://orcid.org/0000-0001-5385-8201
Tatsuya HigashiDepartment of Molecular Imaging and Theranostics, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology (QST-NIRS), Chiba, Japan.
National Institutes for Quantum Science and Technology · JPTohoku University · JPKyoto University Hospital · JP

Funding

AMED-CREST JP18gm0710003Japan Agency for Medical Research and Development JP18am0101078KAKENHI 16K10748KAKENHI 17K07299KAKENHI 17K10497KAKENHI 18H02774KAKENHI 18K07778
6 · The paper itself

Abstract

Podoplanin is a type I transmembrane sialomucin-like glycoprotein that is highly expressed in malignant mesothelioma. The rat-human chimeric antibody NZ-12 has high affinity for human podoplanin and antibody-dependent cellular cytotoxicity and is applicable for radioimmunotherapy (RIT) to enhance the antitumor effect. In the present study, we evaluated the in vivo and in vitro properties of radiolabeled NZ-12 and the antitumor effect of RIT with

Indexed as

AnimalsAntibodies, MonoclonalAntibody-Dependent Cell CytotoxicityCell Line, TumorGene Expression Regulation, NeoplasticHumansIndium RadioisotopesLung NeoplasmsMaleMembrane GlycoproteinsMesotheliomaMesothelioma, MalignantMiceMice, NudePodoplaninRadioimmunotherapyAntibodies, MonoclonalIndium-111Indium RadioisotopesMembrane GlycoproteinsPDPN protein, humanPodoplaninYttrium-90Yttrium Radioisotopesantibodymalignant mesotheliomapodoplaninradiationradioimmunotherapy

Identifiers

PMID30801908
PMCPMC6500970
OpenAlexW2917305596

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.